Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Rifaximin Helps in the Treatment of Irritable Bowel Syndrome: Presented at ACG By Paula Moyer HONOLULU, HI -- November 2, 2005 -- Patients with irritable bowel syndrome (IBS) often get relief from one 10-day course of rifaximin (Xifaxan), according to investigators who presented their findings here November 1st at the 70th annual meeting of the American College of Gastroenterology (ACG). Rifaximin is currently approved for the treatment of traveler's diarrhea but is often used off-label to treat IBS. The current research was designed to see whether the treatment is effective in the IBS setting. "This is the first treatment I've seen for IBS with which the benefit is sustained when the treatment is stopped," said principal investigator Mark Pimentel, MD, Director, GI Motility Program, Cedars-Sinai Medical Center, Los Angeles. "Typically when you stop the treatment, you're right back to baseline." Dr. Pimentel and colleagues randomized 87 patients who met Rome I criteria for IBS to receive either placebo or 400 mg of rifaximin orally three times daily for 10 days. During the treatment phase and for 7 days after treatment ended, subjects completed a stool diary and responded to a symptom questionnaire and lactulose breath test. Subjects and investigators were blinded to the test results. The 43 patients in the rifaximin group had an average overall symptom improvement of 37.7%, compared to compared to 23.4% of the 44 placebo patients (P < .05). In treatment group, 37% of participants were classified as clinical responders, compared to 16% of those in the placebo group. The study defined response as at least a 50% overall improvement. Subjects with diarrhea were more likely than those with constipation to respond to treatment with rifaximin, Dr. Pimentel said. The clinical response among those with diarrhea was 49% for those on rifaximin compared to 23% of those on placebo (P < .05). Bloating was also improved, but not in a statistically significant manner, and the investigators documented no difference in patients with constipation. The study was funded by Salix Pharmaceuticals, Ltd., which manufactures Xifaxan. [Presentation title: Rifaximin, a Non-Absorbable Antibiotic Improves the Symptoms of Irritable Bowel Syndrome: a Double-Blind Randomized Controlled Study. Abstract 42] E-mail this page to a friend or colleague! To print, use this version